Reversal of cancer chemotherapeutic resistance by amphotericin B—A broad phase I–II pilot study

Discordant influence of amphotericin B on epirubicin cytotoxicity in primary hepatic malignant cells collected by a new primary culture technique

“…The actual mechanism for the attenuation of the effect of chemotherapeutic agents by AmB is still unknown and needs to be further investigated. None of the previous clinical trials had evaluated the in vitro influence of AmB on chemotherapeutic cytotoxicity before AmB was applied in systemic chemotherapy 25–29 . Inclusion of patients with a negative AmB effect may lower the total response rate.…”

“…None of the previous clinical trials had evaluated the in vitro influence of AmB on chemotherapeutic cytotoxicity before AmB was applied in systemic chemotherapy. [25][26][27][28][29] Inclusion of patients with a negative AmB effect may lower the total response rate. The benefit of addition of AmB in some particular patients with a positive AmB effect may thus be masked.…”

“…Studies using high concentrations of AmB that are much higher than the acceptable therapeutic serum level usually can obtain a positive in vitro effect of augmentation of the chemotherapeutic cytotoxicity. The benefit of addition of AmB in systemic chemotherapy had been investigated in several clinical trials 25–29 . The results were disappointing and resulted in AmB being abandoned in systemic chemotherapy.…”

“…The benefit of addition of AmB in systemic chemotherapy had been investigated in several clinical trials. [25][26][27][28][29] The results were disappointing and resulted in AmB being abandoned in systemic chemotherapy. However, the mechanisms for the failure of its clinical application remain to be clarified.…”

Chemoresistenz des Nierenzellkarzinoms: Stellenwert der Kalziumantagonisten

“…der Vinca-Alkaloide oder der Anthrazykline, in vitro erhöhen können (1,17). Obwohl die meisten dieser Substanzen aufgrund ihrer pharmakologischen oder toxikologischen Eigenschaften für eine Verwendung als Resistenzdurchbrecher beim Menschen nicht in Betracht kommen, liegen bereits erste klinische Ergebnisse mit Verapamil (2,23,24,27), Chinidin (7), Amiodaron (7) und Amphotericin B (29) bei einigen Tumorarten vor. Derzeit scheint nur die Gruppe der Kalziumanatagonisten, also Medikamente mit Hauptindikation in der Behandlung kardiovaskulärer Erkrankungen, für diesen neuen therapeutischen Einsatz geeignet zu sein (14).…”